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Abstract
Purpose The objective of this study was to compare the
performance characteristics of
18F-fluorodeoxyglucose
(FDG) positron emission mammography (PEM) with breast
magnetic resonance imaging (MRI) as a presurgical imaging
and planning option for index and ipsilateral lesions in
patients with newly diagnosed, biopsy-proven breast cancer.
Methods Two hundred and eight women >25 years of age
(median age=59.7±14.1 years) with biopsy-proven primary
breast cancer enrolled in this prospective, single-site study.
MRI, PEM, and whole-body positron emission tomography
(WBPET) were conducted on each patient within 7
business days. PEM and WBPET images were acquired
on the same day after intravenous administration of
370 MBq of FDG (median=432.9 MBq). PEM and MRI
images were blindly evaluated, compared with final
surgical histopathology, and the sensitivity determined.
Substudy analysis compared the sensitivity of PEM versus
MRI in patients with different menopausal status, breast
density, and use of hormone replacement therapy (HRT) as
well as determination of performance characteristics for
additional ipsilateral lesion detection.
Results Two hundred and eight patients enrolled in the
study of which 87% (182/208) were analyzable. Of these
analyzable patients, 26.4% (48/182), 7.1% (13/182), and
64.2% (120/182) were pre-, peri-, and postmenopausal,
respectively, and 48.4% (88/182) had extremely or hetero-
geneously dense breast tissue, while 33.5% (61/182) had a
history of HRT use. Ninety-two percent (167/182) under-
went core biopsy for index lesion diagnosis. Invasive
cancer was found in 77.5% (141/182), while ductal
carcinoma in situ (DCIS) and/or Paget’s disease were found
in 22.5% (41/182) of patients. Both PEM and MRI had
index lesion depiction sensitivity of 92.8% and both
were significantly better than WBPET (67.9%, p<0.001,
McNemar’s test). For index lesions, PEM and MRI had
equivalent sensitivity of various tumors, categorized by
tumor stage as well as similar invasive tumor size predictions
with Spearman's correlation coefficient of 0.61 for both PEM
and MRI compared to surgical pathology. Menopausal
status, breast density, and HRT did not influence the
sensitivity of PEM or MRI. For 67 additional unsuspected
ipsilateral lesions or multifocal lesions, PEM had sensitivity
of 85% (34/40) and specificity of 74%, (20/27) compared to
MRI's sensitivity of 98% (39/40) and specificity of 48% (13/
27) [p=0.074, for sensitivity; p=0.096 for specificity]
Conclusion PEM is a good alternative to MRI as a
presurgical breast imaging option and its performance
characteristics are not affected by patient menopausal/
hormonal status or breast density.
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The unifying premise in breast cancer screening is that
early diagnosis can result in decreased patient morbidity
and mortality. Breast cancer has seen this type of reduction
since the implementation and attendance of mammographic
screening programs [1, 2]. While mammography and
ultrasound along with physical breast examination saves
lives, it is not perfect since 10–15% of cancers are missed
due to a variety of reasons including observer error, often
because the cancer is hidden by dense normal parenchymal
tissue [3, 4]. Once cancer is identified, an important
diagnostic necessity is the accurate determination of the
full extent of disease, as this directly impacts the type of
surgical intervention and postoperative therapy the patient
receives. Ultrasound, whole-body positron emission tomog-
raphy (WBPET), and magnetic resonance imaging (MRI)
are adjunct diagnostic modalities that have been employed
to assist in determining the stage and extent of breast cancer
prior to surgery. However, breast imaging is responsible for
approximately 1 million surgical and needle breast biopsies
being performed each year for benign findings [5]. In
addition, second and third operations occur because of
positive surgical margins on lumpectomy or partial mas-
tectomy specimens in 40–60% of breast cancer patients [5].
These data highlight the need for improvement in distin-
guishing benign from malignant disease and accurately
determining the extent of disease.
The use of dynamic contrast-enhanced MRI of the breast
for presurgical planning had an enthusiastic start in the
early 1990s. MRI has been successfully implemented in
many medical communities as a valuable tool to diagnose
additional cancer in the same breast (ipsilateral) in up to
one third of patients and is recommended as a supplemental
screening tool to mammography in women considered to be
at high risk for developing breast cancer [6]. A clear
advantage of MRI is that it does not use radioactivity and
detects blood flow to lesions. Also, MRI is more sensitive
and accurate than mammography and ultrasound in detec-
tion of invasive lobular cancer (ILC), which occurs at a
higher rate in women with a history of hormone replace-
ment therapy (HRT) [7]. MRI is sometimes referred to as
molecular imaging because the patient is scanned before
and after the intravascular injection of a contrast agent [8,
9]. Pre-contrast images are “subtracted” from the post-
contrast images, and the kinetics of blood flow to particular
lesions plotted. The increased blood flow is indicative of
vascularization frequently found in cancer. However, the
unprecedented sensitivity of MRI in identifying anatomical
lesions and many benign lesions [10], its lower sensitivity
for detection of in situ cancers [9], lack of uniform MRI-
biopsy capability [11]a n dt h el a c ko fa d h e r e n c et o
guidelines regarding image acquisition and interpretation
hinders its use [12]. Challenges also arise with MRI
interpretation when the breast is under estrogen modulation
(menstrual cycle, HRT) which affects the glandular tissue
of the breast, thus increasing image background [13]. For
many women, the exam is a challenge for other reasons
including claustrophobia, large body size, and implanted
metal devices [14]. Further difficulty arises for those with
impaired renal function for whom the intravenous contrast
is contraindicated [15, 16].
Molecular imaging, using PET, has evolved over the past
decade to become an integral step in the evaluation of
patients with many different types of malignancies [17–19].
An advantage of PET is the use of radiotracers that can
potentially detect cancer even prior to vascularization as
cancer cell metabolism is usually heightened prior to the
stimulation of new vessel growth. However, the use of
WBPET in breast cancer is restricted in part due to the
lower levels of
18F-fluorodeoxyglucose (FDG) tracer
uptake in some breast malignancies compared to other
cancers and the small size of many screen-detected
malignancies [20]. Detection of ILC and ductal carcinoma
in situ (DCIS) with WBPET has been particularly
challenging [20]. High-resolution breast PET, also known
as positron emission mammography (PEM), is a small,
organ-specific PET device with a reported in-plane spatial
resolution of 2 mm. In addition, it has the unique
capability of providing PET biopsy guidance that facili-
tates percutaneous sampling of identified lesions [17, 19].
A published multicenter, retrospective clinical study of 94
patients with equivocal or suspicious mammograms
demonstrated that PEM has a sensitivity of 90%, specific-
ity of 86%, and accuracy of 88% [21].
The main objective of this study was to prospectively
compare the sensitivity of PEM versus breast MRI in
depiction of known malignancies (index lesions) and to
determine the performance characteristics of the two
modalities for additional ipsilateral lesion detection in
patients with newly diagnosed, biopsy-proven breast cancer
as part of their presurgical planning. The sensitivity of PEM
was compared with WBPET imaging on the same radio-
tracer dose administered to the same patients. Substudy
analysis compared the sensitivity of PEM versus MRI with
regards to menopausal status, breast density, and HRT use.
Materials and methods
Patient population
All persons gave their informed written consent prior to
study inclusion. This single-site, prospective, Institutional
Review Board-approved study (Boca Raton Regional
Hospital) was designed and funded by the Radiology
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FL, USA) to test the role of PEM and MRI in presurgical
management of patients with newly identified, histopatho-
logically characterized breast cancer lesions.
Women who were >25 years (median age=59.7±
14.1 years, range 29–87) were approached for participation
from 1 September 2006 to 1 August 2008. In addition to
patient age, clinical findings, and family history, medications
and the presence of coexisting medical conditions were
recorded.
All women had biopsy-proven primary breast cancer and
were required to have a mammogram within 3 months prior
to enrollment and were not participating in a similar,
competing protocol [22]. The average time period between
the diagnostic biopsy and imaging was 11.9 days. PEM,
MRI, and WBPET imaging were conducted on each patient
within 7 business days. The order of PEM and MRI
imaging was dependent on device availability as is typical
in routine clinical practice. To minimize radiation to the
patient, the protocol allowed patients to be imaged by PEM
followed by WBPET on the same dose of radiotracer. The
patient’s family history and medications were recorded and
those who were pregnant, lactating, had type 1 or
uncontrolled type 2 diabetes mellitus, or scheduled for a
sentinel node procedure within 6 h of the PEM study were
excluded. Those patients who had any tissue sampling
intervention between PEM or MRI imaging, or underwent
neoadjuvant chemotherapy or hormone therapy prior to
definitive surgery, were excluded from analysis. For
purposes of this scientific communication, we will focus
on the data generated for index and additional ipsilateral
lesion characterization by PEM and MRI.
MRI image acquisition
A 1.5-T Symphony whole-body system (Siemens Medical
Solutions, Malvern, PA, USA), a 7-channel breast array
coil, and an IV angiocatheter (minimum 20-gauge) in an
antecubital fossa vein connected to a power injector were
used. The imaging protocol consisted of an initial rapid
gradient-echo scout localization sequence acquired in all
three orthogonal planes. Non-contrast sequences included a
turbo short τ inversion recovery (STIR) coronal sequence
to image the breast, T spine, and axillary regions [30
sections; each section 4 mm and skip 1 mm; 340-mm field
of view; repetition time (TR)/echo time (TE) 4030/30;
inversion time 150 ms; turbo factor 7; matrix 253×384; and
1 acquisition, a turbo T2-weighted axial sequence, 80
sections; each section 2 mm, no gap, 340-mm field of view;
TR 8870/146; turbo factor 19; matrix 384×512; and 1
acquisition]. Dynamic FLASH 3-D (three-dimensional fast
low-angle shot) contrast-enhanced series were performed
using the following parameters: radiofrequency spoiled
gradient-echo; no fat suppression; 5 measurements (series);
80 sections; each section 2 mm at 2-mm intervals; matrix
384×512; 340-mm field of view; 10/4.5; flip angle 25°;
parallel imaging factor of 2, and 1 acquisition (measure-
ment). The scanning time was 2 min 6 s per series time
point. The first time point was acquired before contrast
administration. During a subsequent pause of 25 s, a single
dose of gadopentetate dimeglumine (0.1 mmol/kg, Mag-
nevist, Berlex, Montville, NJ, USA) was injected at a rate
of 2 ml/s and was immediately followed by a 20-ml normal
saline flush injected at a rate of 1 ml/s. Series 2–5 were then
acquired sequentially with no interscan delays. Initial and
delayed dynamic images were obtained within 8 min after
the injection of contrast material. Centric spatial encoding
was used for all sequences.
PEM/WBPET image acquisition
Patients were required to fast for 4–6 h. The fasting blood
glucose was measured and those with levels less than
7.8 mmol/l (mean=5.4 mmol/l, range 3.6–7.7 mmol/l) were
injected with FDG (370 MBq, median dose 432.9 MBq,
range 344.1–577.2 MBq). Patients were asked to rest
quietly for 60 min (mean=77, range 26–208 min) to allow
the radiotracer to circulate after which bilateral 10-min
craniocaudal (CC) and mediolateral oblique (MLO) acquis-
itions were obtained with the Naviscan PEM scanner
(Naviscan, Inc., San Diego, CA, USA) (see Fig. 1a, b).
Additional views (axillary, cleavage, or mediolateral,
axillary tail, lateral) were obtained at the discretion of the
physician (refer to www.naviscan.com/positioning).
WBPET images were obtained immediately following
PEM imaging (approximately 122 min after radiotracer
injection) with the patient lying in the supine position using
a Siemens CTI/HR+WBPET (Siemens Medical Solutions,
Malvern, PA, USA); 7-min emission/3-min transmission
acquisitions from the base of the skull to the upper thigh were
obtained. The transmission scans were interleaved between
multipleemissionscanstocorrect for nonuniformattenuation.
The images were reconstructed using an iterative reconstruc-
tion algorithm and both attenuation-corrected and non-
attenuation-corrected images were interpreted visually. Slice
thickness and slice interval were both 4 mm.
Image interpretation
Mammograms, MRI, and PEM images were reviewed by
one of six rotating Mammography Quality Standards Act
certified radiologists at the Boca Raton Regional Hospital.
All examinations were interpreted according to the Amer-
ican College of Radiology Breast Imaging Reporting and
Data System (BI-RADS) with BI-RADS 4 and above treated
as suspicious for malignancy. Physicians were requested to
Eur J Nucl Med Mol Imaging (2011) 38:23–36 25review the image with access to conventional imaging
(mammography or ultrasound) but without influence of the
alternative (PEM versus MRI) imaging modality. WBPET
images were reviewed in three orthogonal planes on a
dedicatedPETworkstationandinterpretedbyaboardcertified
nuclear physician who did not have access to PEM images.
Relevant demographic, clinical history, image interpretation,
biopsy,andfinalsurgicalpathologyinformationwas collected
using case report forms.
Quantitative FDG uptake
A ratio of FDG uptake between the lesion in question and the
background glandular tissue was used to determine the risk
assessment of malignancy on PEM images. First, a region of
interest (ROI) was drawn including normal ipsilateral breast
tissue and the average or mean called a PEM uptake value
wasrecorded(PUVmean). Next an ROI was drawn around the
lesion in question and the maximum FDG uptake (PUVmax)
recorded. The ratio of the PUVmax of the lesion to the
PUVmean of the background (LTB) was calculated and
recorded. The architectural distribution of FDG uptake,
i.e., focus, linear or ductal, mass, non-mass distribution
etc., and LTB was used to determine the assessment
according to a proposed PEM lexicon based on MRI
Breast Imaging Reporting and Data System (BI-RADS)
[23] and was provided to investigators as part of their
PEM interpretive training. Briefly, an LTB ratio of 2.0 and
focal localization was considered suggestive of malignan-
cy warranting biopsy or BI-RADS 4 categorization [24,
25]. An LTB ratio less than 1.5 was considered most likely
benign and ratios between 1.5 and 2.0 were rated as
suspicious dependent on the architecture for FDG uptake.
Lesions seen on WBPET were localized and the
maximum standardized uptake value (SUVmax)w a s
used to determine malignancy. An ROI was drawn
around the abnormality and the SUV recorded in the
clinical report. The SUVmax has been shown to be
significantly influenced by histological grade, invasive-
ness, and hormonal receptor status of the primary tumor
[26, 27].
Final surgical histopathological correlation of index
and ipsilateral lesions
Approximately 3 weeks after PEM and WBPET (mean=
18.9±15.1 days, min.=1 day, max.=110 days), patients
underwent surgery for excision of the primary tumor. Final
surgical pathology was classified as invasive carcinoma
[invasive lobular carcinoma (ILC), invasive ductal carcinoma
(IDC), invasive tubulolobular carcinoma (ITLC), invasive
micropapillary carcinoma (IMPC)], in situ carcinoma [ductal
carcinomas in situ (DCIS) or Paget’sd i s e a s e ] ,high risk
[atypical ductal hyperplasia (ADH), atypical lobular hyper-
plasia (ALH)], or benign pathology [fatty necrosis, inflam-
mation (biopsy site), fibrocystic change (FCC)].
Index lesion size on imaging was compared to size on
surgical pathology. The largest diameter in each case was
used to calculate lesion size. Ipsilateral lesions were
classified as invasive and in situ carcinoma (IDC, ILC/
ITLC, IDC/ILC/DCIS, IDC/DCIS, DCIS), high risk [ADH,
ALH, lobular carcinoma in situ (LCIS)], or benign
[fibroadenoma (FA), FCC].
Data collection and image analysis
The sensitivity was calculated for each modality based on
interpretations for 182 index lesions. The sensitivity,
specificity, and accuracy were calculated for the 67
additional ipsilateral lesions. Abbreviations were as fol-
lows: N, number of patients; TP, true-positive; TN, true-
negative; FN, false-negative; FP, false-positive. If the final
pathology for index lesions showed no residual carcinoma,
the lesions were classified as “FP” if they were depicted as
carcinoma on the imaging modality or “TN” if they were
not seen on the imaging modality. Sensitivity was calculat-
ed using the following formula: TP/(TP + FN). For
additional ipsilateral lesions, the following formulas were
used for calculation of specificity: TN/(FP + TN); accuracy:
(TN + TP)/(TN + TP + FN + FP); positive predictive values
(PPV): TP/(TP + FP); and negative predictive values
(NPV): TN/(FN + TN). Performance characteristics were
expressed as percentages.
CC MLO
b a
Fig. 1 Positioning of subjects
in the PEM scanner for image
acquisition in the CC and MLO
positions are shown in a and b,
respectively
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The data were presented as mean ± standard deviation (SD).
Stata software (StataCorp LP, College Station, TX, USA) was
used for statistical analysis and p values less than 0.05 were
considered to represent a significant difference between two
populations. The 95% confidence intervals (CI) for the
binary test measures (sensitivity, specificity, and accuracy)
were calculated using exact binomial confidence intervals.
McNemar’s test was performed on comparisons of the same
group of cases when comparing different imaging modalities
(comparison of performance between PEM and WBPET or
PEM and MRI or MRI and WBPET). Chi-square tests were
used to evaluate the effect of breast density, menopausal
status, and HRT use on the sensitivity of PEM and MRI.
Spearman's rank correlation coefficient was used to measure
the correlation between size and histology. No adjustments
were made for multiple comparisons.
Results
Demographics and relevant clinical history
In the study, 250 patients were approached, 11 declined and
239 patients were enrolled. A total of 31 were subsequently
disqualified: 2 because they did not have a primary breast
malignancy, 17 because they received neoadjuvant chemother-
apy prior to surgical intervention, 3 due to incomplete imaging
(1 refused MRI imaging and 2 subjects withdrew from the
study), and 9 were disqualified because they had no final
surgical pathology due to withdrawal from the study center. An
additional 26 patients were ineligible because the MRI or PEM
imaging was performed before study entry, leaving a total of
182 analyzable patients (87.5%, 182/208) (Table 1). One
hundred sixty-seven women had residual tumor at surgery.
The demographics and relevant clinical history of
patients enrolled, analyzed, and who had residual tumor
on final surgery are summarized in Table 2. The demo-
graphics were similar across the patient groups. Of the 182
patients that were analyzable, 26.4% (48/182), 7.1% (13/
182), and 66.0% (120/182) were pre-, peri-, and postmen-
opausal, respectively, and 48.4% (88/182) had extreme or
heterogeneously dense breast tissue. The majority of
patients had not used HRT (63.7%, 116/182), while 61 of
182 (33.5%) subjects did have a history of HRT use prior to
inclusion in the study.
Histopathology of biopsied lesions
Of the lesions studied, 45.6% (83/182) were clinically
palpable and 54.4% (99/182) were not. The majority of the
lesions (91.8%; 167/182) were sampled using a vacuum-
assisted core biopsy approach and the remainder had
excision, punch/shave, fine-needle aspiration, and unknown
biopsy procedures, respectively (Table 3). Pathology
showed that invasive disease was found in 77.5% (141/
182) of patients and DCIS (20.9%) and Paget’s disease
(1.6%) was found in 22.5% (41/182).
Index lesion image analysis
Both PEM and MRI had an index lesion detection
sensitivity of 92.8% (95% CI, range 88–96%, N=182)
and both were significantly better than the 67.9% (95% CI,
range 60–70%, N=173) sensitivity obtained with WBPET
(p<0.001, McNemar’s test). Nine subjects did not undergo
WBPET imaging. There was no significant difference in the
sensitivity between PEM and MRI (p=NS, McNemar’s
test).
Table 4 summarizes the sensitivity as categorized by
tumor stage in the 167 subjects who had residual cancer at
final surgical treatment. The other 15 had no cancer found at
final surgery. Of these 167 index lesions, 30 were DCIS, and
PEM detected 90.0% (27/30), while MRI detected 83.0%
(25/30) (p=NS). One hundred and thirty-seven index lesions
were invasive cancer of which PEM detected 93.4% (128/
137), while MRI detected 94.9% (130/137) (p=NS). Both
modalities have comparable sensitivity in depiction of
invasive cancer of different sizes (1 mm to >50 mm), while
the sensitivity of PEM was 100.0% for T1a invasive cancer
in this small series. The imaging concordance with specific
pathology is summarized in Table 5. There were 137
invasive cancer cases, 30 in situ, 4 high risk, and 11 benign.
The sensitivities of PEM and MRI for invasive carcinoma
were comparable (PEM=93.4% and MRI=94.9%). PEM
however was slightly more sensitive in the detection of
Table 1 Participant enrollment summary
Participant summary Number of
participants
Subjects approached 250
Subjects who declined participation 11
Subjects enrolled 239
Ineligible because did not have primary
breast malignancy
2
Disqualified due to treatment with
neoadjuvant chemotherapy
17
Disqualified due to failure to complete
imaging protocol
3
Disqualified due to lack of final pathology 9
Subjects with complete data 208
Disqualified because MRI or PEM was performed
prior to study entry
26
Analyzable subjects 182
Subjects with residual tumor at final pathology 167
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tumor at index lesion site (sensitivity of PEM=72.7% vs
MRI=54.6%).
The sensitivities for index lesion depiction when catego-
rized by menopausal status, breast density, and HRT use are
summarized in Table 6. Neither menopausal status nor breast
density affected lesion detection sensitivity of either PEM or
MRI (p>0.05, chi-square test). Although PEM was very
similar to MRI in the depiction of cancer lesions, there were
some cases where PEM appeared to be more sensitive. For
example a 62-year-old woman who had a history of using
HRT presented with a 1.8-cm ill-defined solid mass at 4
o’clock in the right breast by mammography that was
diagnosed at pathology to be invasive mammary carcinoma
with lobular features (grade I). The lesion was clearly
detected in the right breast by PEM, but missed by MRI
(Fig. 2a). As shown in the PEM images (Fig. 2b, c), a focal
area of increased FDG activity corresponding to the biopsy-
proven malignancy in the inner lower quadrant approximate-
ly 1 cm from the nipple and measuring approximately 1.3×
0.8×0.5 cm was clearly observed.
Final surgical pathology of all index lesions is summa-
rized in Table 7. Final surgical pathology confirmed that
75.0% (137/182) of the index lesions were invasive cancer
with 16.5% carcinoma in situ (30/182) and 2.2% (4/182)
were considered high risk lesions with presumably the
original cancer removed at biopsy. Six percent (11/182)
w e r ef o u n dt ob er e s i d u a lb e n i g np r o c e s s e ss u c ha s
inflammation, fat necrosis, or FCC. The difference in the
number of invasive cancers between the final surgical
pathology results and biopsy results is presumed to reflect
the complete removal of the malignancy at biopsy and post-
biopsy inflammatory changes.
The size range of the invasive index tumors as
measured by PEM and MRI were compared to the final
surgical specimen as shown in Table 8. The average,
median, and minimum sizes of the lesions identified by
MRI, PEM and surgical pathology showed similar values.
Spearman's correlation coefficients for size on imaging vs.
histopathology were 0.61 for both PEM and MRI.
However, PEM tended to overestimate the size in the
largest lesion compared to surgical pathology and MRI
Characteristic Enrolled participants,
N=208 (%)
Analyzed participants,
N=182 (%)
Participants with residual
tumor at final pathology,
N=167 (%)
Race
White 194 (93.3) 168 (92.3) 155 (92.8)
African American 1 (0.5) 1 (0.6) 1 (0.6)
Asian 2 (1.0) 2 (1.1) 1 (0.6)
Other/unknown 11 (5.3) 11 (6.0) 10 (6.0)
Menopausal status
Premenopausal 52 (25) 48 (26.4) 42 (25.2)
Perimenopausal 17 (8.2) 13 (7.1) 12 (7.2)
Postmenopausal 138 (66.4) 120 (66.0) 112 (67.0)
Unknown 1 (0.5) 1 (0.5) 1 (0.6)
History of HRT
No 132 (63.5) 116 (63.7) 106 (61.7)
Yes 71 (34.1) 61 (33.5) 57 (34.1)
Unknown 5 (2.4) 5 (2.8) 4 (2.4)
Previous history of breast cancer
No 187 (89.9) 169 (92.9) 156 (93.4)
Yes 21 (10.1) 13 (7.1) 11 (6.6)
Participants with implants
No 189 (90.9) 166 (91.2) 153 (91.6)
Yes 19 (9.1) 16 (8.8) 14 (8.4)
Breast density
Extremely dense 15 (7.2) 13 (7.1) 12 (7.2)
Heterogeneously dense 88 (42.3) 75 (41.2) 70 (41.9)
Scattered fibroglandular 89 (42.9) 80 (44.0) 71 (42.5)
Fatty 10 (4.8) 9 (5.0) 9 (5.4)
Unknown 6 (2.9) 5 (2.7) 5 (3.0)
Table 2 Participant
demographics
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PEM=120, MRI=95.0].
A total of 12 lesions were missed on both MRI and PEM
imaging and classified as “FN.” For all PEM cases,
competition from high glucose levels could not explain
these findings as review of the blood glucose levels showed
that all were below the 7.8 mmol/l requirement, with an
average value of 5.6 mmol/l. On further review it was
determined that 3 of 12 “FN” PEM index lesions were
missed due to poor patient positioning (cases: 1 ILC, 1
IDC/DCIS, and 1 IDC), such that the portion of the breast
with the lesion was not included in the field of view. Of the
12 cases, 8 had low FDG uptake (cases: 3 DCIS, 3 ILC,
and 2 IDC/DCIS) and the final FN PEM case was a 3 mm
lesion (ILC). Review of FN PEM images of these nine
cases found that four of these images could be identified in
retrospect of which three were in patients with bilateral
breast implants. Of the three cases with bilateral implants,
DCIS was present in two cases and IDC was found in a
Table 3 Summary of index lesion characteristics, type of biopsy, and
histopathology prior to study entry in 182 analyzable subjects with
known cancer
Characteristics Patients, N=182 (%)
Palpable lesion
Yes 83 (45.6)
No 99 (54.4)
Type of biopsy
Core 167 (91.8)
Excisional biopsy 3 (1.7)
Punch/shave 2 (1.1)
Fine-needle aspiration 5 (2.7)
Unknown 5 (2.7)
Biopsy pathology
Invasive disease 141 (77.5)
IDC 89 (48.9)
IDC+DCIS 21 (11.6)
IDC+ILC 4 (2.2)
ILC/ITLC 22 (12.1)
ILC+DCIS 1 (0.5)
Breast cancer (unknown type) 3 (1.7)
Intracystic papillary carcinoma 1 (0.5)
DCIS and Paget’s disease 41 (22.5)
DCIS 38 (20.9)
Paget’s disease 3 (1.7)
IDC invasive ductal carcinoma, DCIS ductal carcinoma in situ, ILC
invasive lobular carcinoma, ITLC invasive tubulolobular carcinoma
Table 4 PEM and MRI sensitivity for depicting known cancers in
167 subjects with residual tumor at final pathology, grouped by tumor
type and size
Index lesions (N=167) PEM,
%( N/N)
Breast MRI,
%( N/N)
DCIS (N=30/167) 90.0 (27/30) 83.0 (25/30)
Invasive cancer (N=137/167) 93.0 (128/137) 95.0 (130/137)
T1a (N=4) 100.0 (4/4) 75.0 (3/4)
T1b (N=21) 85.7 (18/21) 90.5 (19/21)
T1c (N=57) 93.0 (53/57) 94.7 (54/57)
T2 (N=52) 96.2 (50/52) 98.1 (51/52)
T3 (N=3) 100.0 (3/3) 100.0 (3/3)
DCIS ductal carcinoma in situ, T1a tumor >1 mm but ≤5 mm, T1b
tumor >5 mm but ≤10 mm, T1c tumor >10 mm but ≤20 mm, T2 tumor
>20 mm but ≤50 mm, T3 tumor >50 mm
Table 5 PEM and MRI sensitivity for depicting known cancer index
lesions in 182 analyzable subjects, grouped by histopathology at final
treatment surgery
Pathology at surgery Total PEM
sensitivity
MRI
sensitivity
N (%) N (%) N (%)
Invasive
cancer
137 (75) 128 (93) 130 (95)
IDC 56 (31) 55 (98) 51 (91)
IDC-DCIS 53 (29) 50 (94) 53 (100)
ILC 20 (11) 16 (80) 18 (90)
IDC ILC 1 (0.6) 1 (100) 1 (100)
IDC, ILC,
DCIS
1 (0.6) 1 (100) 1 (100)
ILC, DCIS 2 (1) 1 (50) 2 (100)
ITLC 3 (2) 3 (100) 3 (100)
IMPC 1 (0.6) 1 (100) 1 (100)
In situ
carcinoma
30 (17) 27 (90) 25 (83)
DCIS 28 (15) 26 (93) 23 (82)
DCIS with
Paget’s
2 (1) 1 (50) 2 (100)
High risk 4 (2) 2 (50) 2 (50)
ADH 3 (2) 1 (33) 2 (67)
ALH 1 (0.6) 1 (100) 0 (0)
Benign 11 (6) 8 (73) 6 (55)
Fat necrosis 4 (2) 3 (75) 2 (50)
FCC 1 (0.6) 1 (100) 1 (100)
Biopsy site 6 (3) 4 (67) 3 (50)
Total positive
cases
167 (92) 155 (93) 155 (93)
Total negative
cases
a
15 (8) 10 (67) 8 (53)
IDC invasive ductal carcinoma; DCIS ductal carcinoma in situ; ILC
invasive lobular carcinoma; ITLC invasive tubulolobular carcinoma;
IMPC invasive micropapillary carcinoma; ADH atypical ductal hyper-
plasia; ALH atypical lobular hyperplasia; FCC Fibrocystic changes
aIn 15/182 cases, final histopathology was benign, leaving 167 lesions
with residual cancer. PEM and MRI both depicted 155/167 known cancer
lesions with an index lesion depiction sensitivity of 92.8%. For pure DCIS
lesions, PEM sensitivity was 93% (26/28), while MRI was 82% (23/28)
Eur J Nucl Med Mol Imaging (2011) 38:23–36 29single case, and all had asymmetric FDG uptake beyond the
implant surface when compared to the contralateral breast.
In retrospect these cases were suspicious for malignancy;
however, they were interpreted as asymmetric implant-
induced capsular fibrosis. The single IDC case was
appreciated in retrospect and it is unclear why it was
missed on the original interpretation. Of the remaining five
of nine lesions, one lesion was 1 mm in size as determined
by pathology, three cases were ILC of which two were also
not seen on MRI, and finally, one case was “only faintly”
seen on MRI due to its proximity to the biopsy clip and
pathology revealed that the majority of this lesion had been
removed at biopsy which may explain why it was not
visualized on PEM.
Ten cases were classified as FP on PEM and eight cases
were classified FP using MRI. Two lesions, one ADH and
one ALH, were identified by PEM. MRI identified two
lesions of ADH that were classified as FP also. Both of
these are high risk pathologies and their identification is
potentially important in patient management decisions.
Other findings resulting in FP results for both PEM and
MRI were: Fat Necrosis (three and two, respectively), FCC
(same single lesion for both PEM and MRI), and biopsy
site (four lesions on PEM and three on MRI).
Additional ipsilateral lesion image analysis
Of the 182 analyzable patients, a total of 74 additional
ipsilateral lesions were found in 35% (63/182) of patients.
Table 9 summarizes the time of lesion sampling relative to
the PEM or MRI imaging. Seven patients had sampling
interventions done after MRI and before PEM were
eliminated from further analysis, leaving a total of 67
additional ipsilateral lesions for analysis. Performance
characteristics (sensitivity, specificity, accuracy, PPV and
NPV using final histopathology as the “truth”) of the two
modalities are shown in Table 10, and Table 11 summarizes
the final surgical pathology of the ipsilateral lesions. An
Table 6 PEM and MRI lesion depiction accuracy for 182 index
lesions, grouped by different menopausal status, breast densities and
history of HRT use
Category 182 patients
analyzed
PEM
accuracy
MRI
accuracy
N (%) N (%) N (%)
Menopausal status
Premenopausal 48 (26) 42/48 (88) 41/48 (85)
Perimenopausal 13 (7) 12/13 (92) 13/13 (100)
Postmenopausal 120 (66) 105/120 (88) 107/120 (89)
Unknown 1 (0.5) 1/1 (100) 1/1 (100)
Breast density
Extreme density 13 (7) 10/13 (77) 9/13 (69)
Heterogeneous
density
75 (41) 66/75 (88) 67/75 (89)
Scattered
fibroglandular
80 (44) 71/80 (89) 74/80 (93)
Fatty 9 (5) 8/9 (89) 8/9 (89)
Not listed 5 (2.7) 5/5 (100) 4/5 (80)
History of HRT
No 116 (64) 102/116 (88) 104/116 (90)
Yes 61 (34) 54/61 (89) 53/61 (87)
Unknown 5 (2.8) 4/5 (80) 5/5 (100)
Chi-square was used to evaluate the effect of menopausal status on the
accuracy of the imaging modalities; p=0.84 for PEM (NS), p=0.45 for
MRI. Chi-square was used to evaluate the effect of breast density on
the accuracy of the imaging modalities; p=0.38 for PEM (NS), p=0.39
for MRI. Chi-square was used to evaluate the effect of HRT use on the
accuracy of the imaging modalities; p=0.7 for PEM (NS), p=0.46 for
MRI
bc a
Fig. 2 A 62-year-old female
patient presented with a 1.8-cm
ill-defined solid mass at 4
o’clock in the right breast by
mammography that was diag-
nosed at pathology to be inva-
sive mammary carcinoma with
lobular features (grade I). MRI
failed to detect any suspicious
lesions in the right breast (a). b,
c On PEM, a focal area of
increased FDG activity
corresponding to the biopsy-
proven malignancy in the right
breast and the inner lower
quadrant approximately 1 cm
from the nipple and measuring
approximately 1.3×0.8×0.5 cm
was clearly observed (arrows)
30 Eur J Nucl Med Mol Imaging (2011) 38:23–36example case where multifocal disease was seen equally
well on PEM and MRI is shown in Fig. 3.
Of the 40 malignancies in 67 additional lesions, PEM
depicted 34 with a sensitivity of 85%, while MRI depicted
39 with sensitivity of 98%. (P value=0.074). Six cases
were categorized as FN on PEM imaging, while one case
was categorized as FN by MRI. For PEM imaging, three
lesions had poor FDG uptake (two IDC and one ILC) and
could not be appreciated on retrospective evaluation. One
FN lesion was missed due to poor patient positioning (ILC)
as the lesion was not within the field of view. One case,
ITLC, was < 1mm in size and was missed on both PEM
and MRI, while the second case, DCIS, was a small focus
found at pathology.
Of the 27 benign lesions among 67 additional lesions,
PEM specificity was 74% (20/27) while that of MRI was
48% (13/27)[P value=0.096]. A total of 14 FP ipsilateral
lesions were seen on MRI, while only 7 were seen on PEM.
Both PEM and MRI each identified a single case of ADH
which was classified as FP, but its identification is
important and could change surgical planning. Three FAs,
one papilloma, and two cases of FCC were categorized as
FP on PEM. MRI had an additional five cases with FA and
eight with FCC listed in this category. No statistically
significant difference was found between the accuracy of
PEM and MRI in ipsilateral lesion depiction (p=0.81,
McNemar’s test), PPV, or NPV.
Discussion
In the USA an estimated 194,280 new cases of breast
cancer are diagnosed each year with an estimated 40,610
annual deaths [28]. In addition, approximately 1 million
surgical and needle breast biopsies a year are performed on
benign tissue with a frequent occurrence of additional
operations for positive or close surgical margins on partial
mastectomy patients [3]. Precise and accurate imaging
technology may improve the accuracy of partial mastecto-
mies and develop consistent strategies for presurgical
management. Although a relatively new technology, several
studies have reported the sensitivity, specificity, and
accuracy of PEM in detection of breast cancer lesions [21,
29–31]. Overall, these series have shown good specificity
(86%) and sensitivity (90%) and are predicted to be better
than WBPET scanners. However, to date, none of these
studies have directly compared PEM with MRI and
WBPET imaging within the same patient population.
The present trial demonstrates that PEM has comparable
sensitivity to MRI in depiction of index and ipsilateral
lesions. The sensitivity of MRI and PEM were both 92.8%
for index lesions and for depiction of additional unsuspect-
Table 7 Comparison of biopsy and final surgical histology for 182
index lesions
Pathology Biopsy Final surgical
pathology before study entry
N=182 (%) N=182 (%)
Invasive carcinoma 141 (77.5) 137 (75.3)
IDC 89 (48.9) 56 (30.8)
IDC+DCIS 21 (11.6) 53 (29.1)
ILC/ITLC 22 (12.1) 23 (12.6)
IDC+ILC 4 (2.2) 1 (0.5)
ILC+DCIS 1 (0.5) 2 (1.1)
IDC+ILC+DCIS – 1 (0.5)
IMPC – 1 (0.5)
Breast cancer (unknown type) 3 (1.7) –
Intracystic papillary ca. 1 (0.5) –
In situ carcinoma 41 (22.5) 30 (16.5)
DCIS 38 (20.8) 28 (15.4)
DCIS+Paget’s disease – 2 (1.1)
Paget’s disease 3 (1.7) –
High risk – 4 (2.2)
ADH/ALH/LCIS 4 (2.2)
Benign pathology – 11 (6.0)
Fat necrosis – 4 (2.2)
Inflammation (biopsy site) – 6 (3.3)
FCC 1 (0.5)
IDC invasive/infiltrating ductal carcinoma; DCIS ductal carcinoma in
situ; ILC invasive lobular carcinoma; ITLC invasive tubulo-lobular
carcinoma; ADH atypical ductal hyperplasia; LCIS lobular carcinoma
in situ; ALH atypical lobular hyperplasia; IMPC invasive micro-
papillary carcinoma; FCC fibrocystic change. (–) Not assessed
Table 8 Index lesion size of invasive tumors (N=114)
Average lesion
size (mm±SD)
Median lesion
size (mm)
Minimum lesion
size (mm)
Maximum lesion
size (mm)
Surgical pathology 20.6±13.9 18.0 4.0 95.0
PEM 19.6±14.1 17.5 3.0 120.0
MRI 19.7±12.5 18.0 2.0 95.0
Only invasive tumors where the largest tumor diameter was reported for PEM, MRI and final treatment surgery were included in this analysis.
DCIS lesions and those with no residual tumor at surgery were excluded in this analysis
Eur J Nucl Med Mol Imaging (2011) 38:23–36 31ed ipsilateral lesions, the sensitivity of PEM was 85.0% and
97.5% for MRI, and were not significantly different from
each other. The high sensitivity of MRI for index and
ipsilateral lesions in this study is on the high end of the
reported 85–100% range [6]. This high sensitivity is most
likely due to inclusion of known malignancies in sensitivity
analyses, and the fact that 38/67 additional ipsilateral
lesions had been biopsied prior to imaging. Both MRI and
PEM had comparable sensitivities for DCIS and for
invasive cancer of various stages. Final surgical patholog-
ical analysis of invasive tumors, excluding DCIS and
lesions with no malignancy, confirmed that PEM and MRI
were good in prediction of average, median, and minimum
size lesions, though PEM tended to overestimate the largest
lesion detected compared to surgical pathology and MRI.
This may be a result of the limited tomography of PEM
imaging where the number of projections is constrained by
the limited angular sampling capable with planar detectors.
Like PEM, others have shown that with both ultrasound
and MRI disease extent is not infrequently overestimated in
12–29% of patients, respectively, resulting in potentially
unnecessary mastectomy [32]. However, if two different
imaging approaches such as anatomic (MRI) and functional
or metabolic (PEM) identify the same abnormalities, greater
confidence and accuracy should result as shown in Fig. 3,
an example of multifocal disease. For ipsilateral lesions,
MRI had a trend towards better sensitivity compared to
PEM while PEMtrended tohavegreater specificitycompared
to MRI, however neither reached statistical significance
(p=0.074 and p=0.096 respectively). The specificity of MRI
isreportedtovarybetween37and100%[6]. Ipsilateral lesion
specificity in this study was within this range at 48% for
MRI while that of PEM was 75%.
The major substudy analysis of the current investigation
was to compare the sensitivity of PEM and MRI for
depiction of index lesions in women with different
menopausal status, various breast densities, and with a
history of HRT use. These analyses were an important
inclusion to our study design since background breast
density and hormonal status are two factors that have
challenged mammography and MRI breast imagers when it
comes to cancer detection [3, 7, 13]. Others have shown a
benefit of metabolic imaging with FDG in cancer detection
in these situations. For example, studies by Vranjesevic et
al. [33] and Kumar et al. [34] both reported that FDG
uptake increases significantly with breast density, but they
concluded that the highest background levels seen would
not be sufficient to interfere with lesion detection. But it is
clear from previous studies [35] that for MRI, FP findings
increase during a patient’s menstrual cycle due to hormonal
Table 9 Time of ipsilateral lesion sampling relative to PEM and MR
imaging
Time of lesion sampling Number of
ipsilateral
lesions (%)
Number of additional
ipsilateral lesions (%)
After PEM & MRI 24 (83.0) 5 (17.0)
Before PEM & MRI 34 (89.0) 4 (11.0)
After MRI before PEM 5 (71.0) 2 (29.0)
Total 63 (85.0) 11 (15.0)
74 ipsilateral lesions were identified in 63 patients. Of these 7 lesions
were biopsied between PEM and MRI imaging and therefore excluded
from final analysis. A total of 67 ipsilateral lesions in 58 patients were
included in the ipsilateral lesions analysis. Note: 38 analyzed lesions
were biopsied prior to PEM and MRI, including 24 malignancies. For
lesions biopsied after PEM and MRI imaging, PEM sensitivity was
71% (12/17) and MRI sensitivity was 94% (16/17)
Table 10 Performance characteristics of PEM and MRI for 40
additional ipsilateral malignancies among 67 biopsied breast lesions
Modality PEM (%) MRI (%) P-Value
[95%CI] [95%CI]
Sensitivity 34/40 (85) 39/40 (98) 0.074
[70 to 94] [89 to 100]
Specificity 20/27 (74) 13/27 (48) 0.096
[54 to 89] [29 to 68]
Accuracy 54/67 (81) 52/67 (78) 0.81
[69 to 89] [66 to 87]
PPV (biopsies recommended) 34/41 (83) 39/53 (74)
NPV 20/26 (77) 13/14 (93)
McNemar’s test was used to check equality of sensitivity and
specificity of the two modalities and were not significantly different
Table 11 Summary of ipsilateral lesion histopathology at biopsy for
67 additional ipsilateral lesions
Histopathology Lesion N (%) PEM
sensitivity (%)
MRI
sensitivity (%) N=67
Invasive and in
situ carcinoma
40 (60) 34 (85) 39 (98)
IDC 18 (27) 16 (89) 18 (100)
ILC/ITLC 5 (8) 2 (40) 4 (80)
IDC/ILC/DCIS 1 (2) 1 (100) 1 (100)
IDC/DCIS 10 (15) 10 (100) 10 (100)
DCIS 6 (9) 5 (83) 6 (100)
High risk 2 (3) 1 (50) 1 (50)
ADH 2 (3) 1 (50) 1 (50)
Benign 25 (37) 6 (24) 16 (64)
BBT 3 (5) 0 (0) 0 (0)
FA 7 (10) 3 (43) 5 (71)
FCC 15 (22) 3 (20) 8 (53)
IDC invasive/infiltrating ductal carcinoma; DCIS ductal carcinoma in
situ; ILC invasive lobular carcinoma; ITLC invasive tubule-lobular
carcinoma; ADH atypical ductal hyperplasia; BBT benign breast
tissue; FA fibroadenoma; FCC fibrocystic change
32 Eur J Nucl Med Mol Imaging (2011) 38:23–36influences on breast tissue. Analysis of variance on lesion
detection versus breast density or menopausal status in this
study did not find any significant influence of breast
density and menopausal status for either PEM or MRI
imaging, and these data suggest that PEM is an attractive
alternative imaging approach in women with dense breast
tissue or who are pre- or perimenopausal. A recent study by
Mavi et al. [36], involving 250 patients with newly
diagnosed breast cancer of a similar age group to this study
(50.9±9.7 years), showed that FDG uptake decreases as age
increases and breast density decreases. Importantly, they
found menopausal state had no effect on FDG uptake,
which supports our finding of no change in PEM accuracy
with menopausal status. With respect to HRT status, a
growing body of evidence suggests that there is an
association between the use of HRT and a higher risk of
both ILC and invasive-lobular mixed carcinoma [7]. The
data presented here show that PEM is equivalent to MRI for
the detection of index cancers in the 61 subjects who had a
history of using HRT prior to study inclusion (p=NS). For
ILC, PEM depicted 16 of 20 cases (80% sensitivity) in
contrast to 18 of 20 depicted by MRI (90% sensitivity),
suggesting that the two modalities are comparable for ILC
depiction.
The sensitivity of PEM and MRI with WBPET in
presurgical planning for women with known breast cancer
was also compared. Although FDG WBPET has proven to
be highly useful in the diagnosis and staging of a variety of
malignancies, for breast cancer, its sensitivity ranges
between 64 and 96%, with an average of 74% across
multiple studies [37]. The reason for this lower sensitivity is
partially due to both the small size of the cancer at detection
and the lower levels of FDG uptake found in different types
of breast cancer. Preliminary evaluation of PEM for index
lesions found a sensitivity of 90% for invasive malignan-
cies and 91% sensitivity for DCIS [21]. This shows a
substantial improvement for DCIS when compared to the
10% WBPET sensitivity found by Avril et al. [38]. In the
current study, PEM and MRI had an index lesion detection
sensitivity of 92.8% which was significantly better than the
68% found with WBPET (p>0.0001). Studies on dual time
point imaging WBPET have clearly shown improved
discrimination between malignant and benign processes
[39] as well as improved discrimination between noninva-
sive and invasive breast cancers [40] with delayed times at
imaging. Since PEM imaging was done first, WBPET
should have had the detection advantage [40], all else being
equal.
We also performed analysis of FN cases. Previous PET
studies had found that certain early breast tumors, with less
biologically aggressive features, were less glycolytic and
could evade WBPET detection due to insufficient FDG
uptake [41]. Review of the FN PEM cases in this study
found that 11 or 4.4% of the total lesions (index +
ipsilateral) were not visualized due to “lack of FDG
uptake.” Although many were identified in retrospect, of
those that were not, many were small. Thus, the question of
whether these small lesions could have been detected if
PEM imaging had been done at a later time when the
contrast of the lesion increases remains unanswered. To this
point, the PEM scanner manufacturer currently recom-
mends waiting 90 min post-injection of FDG for all PEM-
guided biopsies, specifically to take advantage of the
improved lesion detection that is found at this later time.
Collectively, the data in the present study suggest that
PEM can be used as an adjunct or alternative imaging
b a
Fig. 3 A 61-year-old subject
presented with an area of clus-
tered pleomorphic microcalcifi-
cations in the upper outer
quadrant of the left breast which
proved to be DCIS following
stereotactic biopsy. Anultrasound
confirmed the presence of the
biopsy clip and identified an
additional solitary 7-mm nodule
in the same quadrant. Core sam-
plingfoundthisnoduletobeIDC.
MRI identified a 1.2-cm irregular
enhancing mass (depicted by
arrow) with a possible satellite
lesion (a). PEM confirmed a
1.1×1.0×2.2-cm mass with a
second 0.7×0.7×2.5-cm inferior
mass with final pathology con-
firming IDC and DCIS, respec-
tively (b), as depicted by arrows
Eur J Nucl Med Mol Imaging (2011) 38:23–36 33modality to MRI in presurgical management of breast
cancer patients, which is an important finding since many
patients cannot and will not have a breast MRI for many
reasons [8–16]. The American College of Radiology
Imaging Network 6666 US Screening Protocol recently
published a study of 1,215 women with elevated breast
cancer risk who could, according to protocol guidelines,
undergo breast MRI [42]. In spite of this, only 57.9% of the
eligible patients agreed to participate with claustrophobia
being the major reason for refusal (25.4%). The other
reasons for declining an MRI in consecutive order were
time constraints, financial concern, no physician referral,
lack of interest, medically intolerant to MRI, refusal of
intravenous injection, probable additional biopsy proce-
dures as a result of an MRI, scheduling constraints within a
patient’s menstrual cycle and their hormonal status, travel,
gadolinium-related risks or allergies, and finally unknown
reasons. It is important to note that claustrophobia, the main
reason for refusal of an MRI, and gadolinium-related risks
or allergies are not concerns associated with PEM. In
addition to patient refusal, it has been especially challeng-
ing to implement MRI in community settings partly due to
the lack of recommended standard criteria for image
acquisition and interpretation which has led to variable
practice outcomes and therefore variable acceptance of the
procedure by referring physicians [12]. While MRI has
been successfully implemented in numerous medical
communities as a valuable tool to diagnose ipsilateral
cancer and detect unsuspected contralateral disease in 3–
9% of patients, improving surgical management, these
benefits are not without additional costs and consequences
[43–46]. For instance, MRI equipment and installation
costs are expensive, extensive time is required to train staff
and physicians, and the technique has increased the number
of unnecessary presurgical biopsy procedures. Disappoint-
ingly, studies suggest that only one of four MRI-guided
biopsies finds cancer [47, 48]. Consequently, both referring
surgeons and patients are frustrated with the high rate of FP
findings and resultant patient anxiety.
A limitation of this study, as for many clinical trials, was
disqualification of patients because of poor patient compli-
ance. The patients were also not randomized for imaging,
replicating clinical practice procedures in order to not
compromise patient care and as for most single-site studies,
the population was homogeneous. It is also important to
emphasize that the study design did not address whether or
how PEM image results alone influenced surgical treatment
because all imaging results were made available to the
surgeon prior to surgery. We must also emphasize that PEM
technology is continually developing and physicians are
gaining knowledge on how to utilize this technology
effectively. The present study was conducted using a Solo
I model of the Naviscan PEM scanner that does not have
motorized paddles, like currently commercially available
Solo II PEM scanners developed by Naviscan Inc.; hence,
positioning patients by the technologist for imaging was
difficult, resulting in 25% (3/12) FN index lesions. In order
to overcome some of these limitations, the authors of this
study are participating in a larger multi-site trial that
includes diverse ethnicities and randomization of imaging
modalities using the Solo II with motorized paddles.
PEM imaging can both identify worrisome breast lesions
as well as provide an in vivo characterization of their
glucose metabolism which in malignancies has been shown
to correlate with high growth rates, aggressiveness, and
capillary number [49]. An alternative molecular imaging
approach is breast-specific gamma imaging (BSGI), which
utilizes
99mTc-sestamibi. Direct comparison of PEM and
BSGI is lacking and comparing prospective (PEM imaging)
and retrospective studies (BSGI) is problematic. However, a
study involving 23 subjects compared breast MRI to BSGI
and found a malignancy specificity of 25% for MRI versus
71% for BSGI with equal sensitivity [50]. In another
retrospective study with 146 subjects, BSGI had a higher
96.4% sensitivity at the expense of a lower specificity of
59.5% [51]. For comparison, the prospective study by Berg
et al. [21] involving 94 subjects found PEM to have a 90%
sensitivity with a specificity of 86%, suggesting compara-
ble levels of both sensitivity and specificity within this
subject cohort. This finding suggests imaging glucose
metabolism may provide high sensitivity without a loss in
specificity as is seen with other imaging approaches.
The most important result from this study is that PEM
and breast MRI had the same overall sensitivity for
depiction of index cancerous lesions including invasive
cancer and DCIS. The trend of improved specificity of
PEM for ipsilateral lesion detection warrants future
investigation with a study that is powered to evaluate
this outcome. Thus, PEM should be considered as an
acceptable alternative to breast MRI as a presurgical
managing option for many women who currently cannot
tolerate a breast MRI, have scheduling constraints due to
their hormonal status/menstrual cycle, and for use in
communities struggling to implement a successful breast
MRI program or those patients without access to breast
MRI.
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